Azienda Ospedaliera D Cotugno Hospital of Infectious Diseases Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2007
NCT00495846
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

lanreotide (somatuline depot) (1 trial)

octreotide (sandostatin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2